Relationship between single nucleotide polymorphisms in IL28B gene and response to interferon treatment in chronic hepatitis B patients.
- Author:
Chu-ming CHEN
1
;
Fu-yuan ZHOU
;
Yuan-ping ZHOU
;
Yan-li ZENG
;
Wei LI
;
Jin-lin HOU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Alleles; Antiviral Agents; therapeutic use; Female; Genotype; Hepatitis B e Antigens; blood; Hepatitis B, Chronic; genetics; therapy; Humans; Interferons; therapeutic use; Interleukins; genetics; Male; Polymorphism, Single Nucleotide; Young Adult
- From: Journal of Southern Medical University 2011;31(12):2012-2015
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the relationship between the single nucleotide polymorphisms (SNPs) of rs12979860 and rs8099917 in IL28B gene and the response to interferon treatment in hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B patients.
METHODSPeripheral blood samples were collected from 82 HBeAg-positive patients with chronic hepatitis B receiving interferon treatment, including 38 with favorable response to the treatment and 44 without response. IL28B gene was amplified from the chromosomal DNA, and rs8099917 SNP was genotyped based on PCR-RLFP and rs12979860 SNP by sequencing.
RESULTSIn the responsive patients, the distribution frequencies of TT and TG+GG genotypes and allele G in SNPrs8099917 were 81.6% (31/38), 18.4% (7/38), and 9.2% (7/76), as compared to the frequencies of 97.7% (43/44), 2.3% (1/44), and 1.1% (1/88) in nonresponsive patients, respectively. The frequencies showed significant differences between the responsive and nonresponsive patients (P=0.014 for genotypes and P=0.025 for allele G). The distribution frequencies of CT genotypes and allele T in SNPrs12979860 showed no differences between the responsive and nonresponsive patients (P<0.05).
CONCLUSIONrs8099917 SNP is probably associated with the response to interferon treatment in HBeAg-positive patients with chronic hepatitis B, and Allele G may be predictive of the treatment success.